← Eichor
Study identifier: NCT05843786 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Human Recombinant Interferon Gamma in the Treatment of Ventilator-acquired Pneumonia in ICU Patients

Condition: Pneumonia, Ventilator-Associated  ·  Sponsor: Hospices Civils de Lyon

PhasePhase 3
Planned participants132
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Clinical presentation of patients after severe injury such as a severe infection, trauma or extensive burns is characterized by the simultaneous occurrence of dysregulation of the initial inflammatory response and immunosuppression associating quantitative and functional alterations of innate and adaptive immune cells. These acquired immune dysfunctions have been associated with an increased susceptibility to nosocomial infections, foremost among which are ventilator-associated pneumonia (VAP). Despite the implementation of a set of preventive measures, the incidence of these VAP remains high in intensive care, with rates in Europe of 1.5% per day of ventilation. Post-aggressive immunosuppression is characterized by the decrease in the expression of HLA-DR (belonging to the type II major histocompatibility complex, MHC-II) on the surface of monocytes (mHLA-DR). The administration of interferon gamma (IFNγ) can restore the level of mHLA-DR and may possibly improve the prognosis as an adjuvant therapy associated to antibiotics. However, the level of proof of this therapeutic strategy is low, limited to small cohorts of patients, or clinical studies without prior immunodepression assessment. The objective of this study is to conduct a randomized, double-blind, placebo-controlled superiority trial to assess the effect of IFNγ administration on the duration of mechanical ventilation following the first episode of VAP in patients having an HLA-DR \< 8000 AB/C All reported data ab…

This description comes directly from the study's public registry record.

Talk to the study team

Anne-Claire LUKASZEWICZ, Pr  ·  472 11 13 27  ·  anne-claire.lukaszewicz@chu-lyon.fr

Camille BOUCHENY  ·  4 26 73 27 39  ·  Camille.boucheny@chu-lyon.fr

Always discuss trial participation with your own doctor first.

Locations (9)

CHU LimogesLimoges, FranceNot Yet Recruiting
Service civilo-militaire d'Anesthésie-Réanimation et Médecine PériopératoireLyon, FranceRecruiting
Service de reanimation chirurgicale Hopital Croix-RousseLyon, FranceNot Yet Recruiting
Service de reanimation médicale hôpital de la Croix-RousseLyon, FranceRecruiting
Hôpital Edouard Herriot - Médecine intensive - réanimationLyon, FranceNot Yet Recruiting
Service d'anesthésie-réanimation, unité de réanimation chirurgicale PicardNancy, FranceNot Yet Recruiting
Médecine intensive- RéanimationParis, FranceRecruiting
Service d'Anesthésie-réanimation-médecine intensive Hôpital Lyon SudPierre-Bénite, FranceRecruiting
Département Anesthésie-RéanimationSaint-Etienne, FranceNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05843786